|1.||O'Boyle, Niamh M: 2 articles (06/2013 - 09/2012)|
|2.||Zisterer, Daniela M: 2 articles (06/2013 - 09/2012)|
|3.||Meegan, Mary J: 2 articles (06/2013 - 09/2012)|
|4.||Greene, Lisa M: 2 articles (06/2013 - 09/2012)|
|5.||Kelly, Patrick: 1 article (06/2013)|
|6.||Bright, Sandra A: 1 article (06/2013)|
|7.||Reid, Jane E: 1 article (06/2013)|
|8.||Wang, Shu: 1 article (06/2013)|
|9.||Nolan, Derek P: 1 article (09/2012)|
|10.||Lippy, Jonathan: 1 article (03/2008)|
08/01/1994 - "A key chiral intermediate [(3R-cis)-3-(acetyloxy)-4-phenyl-2-azetidinone (2)] for the semi-synthesis of paclitaxel (taxol; 5), an anti-cancer compound, was prepared by an enzymic process. "
09/01/2003 - "Regulation of their catalytic activity both in vitro and in vivo by compounds designed on the cephalosporin, penicillin and 2-azetidinone base was successfully exploited in the treatment of inflammatory, respiratory, cardiovascular disorders, cancer and other pathologic processes. "
04/01/2002 - "Ezetimibe [SCH 58235; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone], a selective cholesterol absorption inhibitor, is being developed for the treatment of primary hypercholesterolemia. "
03/09/2001 - "Ezetimibe (1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone) potently and selectively inhibits the intestinal absorption of cholesterol, thereby reducing plasma cholesterol in preclinical models of hypercholesterolemia. "
09/01/2012 - "In this report, we demonstrate for the first time that prolonged exposure to CA-4 and an azetidinone cis-restricted analogue, CA-432 (chemical name; 4-(3-Hydroxy-4-methoxyphenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)-azetidin-2-one) induced autophagy in adenocarcinoma-derived CT-26, Caco-2 and HT-29 cells but not in fibrosarcoma-derived HT-1080 cells. "